Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SGS and Bavarian Nordic Form Vaccine Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

SGS and Bavarian Nordic Form Vaccine Collaboration

Will develop a novel and differentiated challenge model for respiratory syncytial virus

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

SGS has entered into collaboration with Bavarian Nordic A/S, an international biotechnology company specializing in vaccines, to develop a new respiratory syncytial virus (RSV) challenge strain. This will assist with the advancement of a universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of RSV.

The project will build upon the results of phase II trials undertaken by Bavarian Nordic, and will include a human challenge study, which will be carried out at the SGS Clinical Pharmacology Unit in Antwerp, Belgium, using the new RSV challenge strain, once it has been fully developed and validated.
 
“This partnership combines expertise from both companies with a view to bring a truly life changing therapy to the market. SGS’s experience in both virus development, and in conducting human challenge trials safely and to exacting standards provides the potential to gain efficacy data concerning the vaccine prior to initiating a phase III study,” said Adrian Wildfire, project director, infectious diseases and human challenge unit, SGS.
 
The collaboration comes after SGS’s success in the development of a novel GMP-manufactured, non-hemagglutinating, wild-type strain of Influenza A H3N2 (A/Belgium/4217/2015) which is approved for use as a challenge agent in studies demonstrating the early efficacy of influenza drugs and vaccines in healthy volunteers.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics